Literature DB >> 8649189

Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells.

C Dehmlow1, N Murawski, H de Groot.   

Abstract

The effects of the flavonoid silibinin, which is used for the treatment of liver diseases, on the formation of reactive oxygen species and eicosanoids by human platelets, white blood and endothelial cells were studied. Silibinin proved to be a strong scavenger of HOCI (IC50 7 microM), but not of O2- (IC50 > 200 microM) produced by human granulocytes. The formation of leukotrienes via the 5-lipoxygenase pathway was strongly inhibited. In human granulocytes IC50-values of 15 microM and 14.5 microM silibinin were detected for LTB4 and LTC4/D4/E4/F4 formation, respectively. In contrast to this, three- to fourfold silibinin concentrations were necessary to half maximally inhibit the cyclooxygenase pathway. For PGE2 formation by human monocytes an IC50-value of 45 microM silibinin was found. IC50-values of 69 microM and 52 microM silibinin were determined for the inhibition of TXB2 formation by human thrombocytes and of 6-K-PGF1 alpha formation by human omentum endothelial cells, respectively. Thus, the deleterious effects of HOCI that can lead to cell death, and those of leukotrienes that are especially important in inflammatory reactions, can be inhibited by silibinin in concentrations that are reached in vivo after the usual clinical dose. Silibinin is thought not only to display hepatoprotective properties but might also be cytoprotective in other organs and tissues.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8649189     DOI: 10.1016/0024-3205(96)00134-8

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  21 in total

1.  The antioxidant silybin prevents high glucose-induced oxidative stress and podocyte injury in vitro and in vivo.

Authors:  Khaled Khazim; Yves Gorin; Rita Cassia Cavaglieri; Hanna E Abboud; Paolo Fanti
Journal:  Am J Physiol Renal Physiol       Date:  2013-06-26

Review 2.  The use of silymarin in the treatment of liver diseases.

Authors:  R Saller; R Meier; R Brignoli
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Flavonoid combinations cause synergistic inhibition of proinflammatory mediator secretion from lipopolysaccharide-induced RAW 264.7 cells.

Authors:  Omar A Harasstani; Saidi Moin; Chau Ling Tham; Choi Yi Liew; Norazren Ismail; Revathee Rajajendram; Hanis H Harith; Zainul A Zakaria; Azam S Mohamad; Mohamad R Sulaiman; Daud A Israf
Journal:  Inflamm Res       Date:  2010-03-11       Impact factor: 4.575

4.  Topical use of a silymarin-based preparation to prevent radiodermatitis : results of a prospective study in breast cancer patients.

Authors:  Martina Becker-Schiebe; Ulrich Mengs; Margitta Schaefer; Michael Bulitta; Wolfgang Hoffmann
Journal:  Strahlenther Onkol       Date:  2011-07-22       Impact factor: 3.621

Review 5.  Targeting tumor microenvironment with silibinin: promise and potential for a translational cancer chemopreventive strategy.

Authors:  Gagan Deep; Rajesh Agarwal
Journal:  Curr Cancer Drug Targets       Date:  2013-06       Impact factor: 3.428

6.  Neurotrophic and neuroprotective effects of milk thistle (Silybum marianum) on neurons in culture.

Authors:  Smita Kittur; Skuntala Wilasrusmee; Ward A Pedersen; Mark P Mattson; Karen Straube-West; Chumpon Wilasrusmee; Burk Lubelt; Dilip S Kittur
Journal:  J Mol Neurosci       Date:  2002-06       Impact factor: 3.444

7.  Hepatoprotective effects of the nitric oxide donor isosorbide-5-mononitrate alone and in combination with the natural hepatoprotectant, silymarin, on carbon tetrachloride-induced hepatic injury in rats.

Authors:  Omar Mohamed E Abdel Salam; Amany A Sleem; Nermeen Shafee
Journal:  Inflammopharmacology       Date:  2010-01-14       Impact factor: 4.473

8.  Silymarin downregulates COX-2 expression and attenuates hyperlipidemia during NDEA-induced rat hepatocellular carcinoma.

Authors:  Gopalakrishnan Ramakrishnan; Carmen Martha Elinos-Báez; Sundaram Jagan; Titto Alby Augustine; Sattu Kamaraj; Pandi Anandakumar; Thiruvengadam Devaki
Journal:  Mol Cell Biochem       Date:  2008-03-31       Impact factor: 3.396

9.  Cardioprotective activity of silymarin in ischemia-reperfusion-induced myocardial infarction in albino rats.

Authors:  Pragada Rajeswara Rao; Routhu Kasi Viswanath
Journal:  Exp Clin Cardiol       Date:  2007

10.  The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study.

Authors:  Carmela Loguercio; Alessandro Federico; Marco Trappoliere; Concetta Tuccillo; Ilario de Sio; Agnese Di Leva; Marco Niosi; Mauro Valeriano D'Auria; Rita Capasso; Camillo Del Vecchio Blanco
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.